|
Patients with paroxysmal nocturnal hemoglobinuria demonstrate a prothrombotic clotting phenotype which is improved by complement inhibition with eculizumab |
Aug 2020 |
American Journal of Hematology |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
|
TP53 mutations in myelodysplastic syndromes and secondary AML confer an immunosuppressive phenotype |
Jul 2020 |
Blood |
Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS) |
|
Letter to the Editor: Allogeneic hematopoietic stem cell transplantation in elderly patients with acute myeloid leukemia or myelodysplastic syndromes: myth and reality |
Jul 2020 |
Leukemia |
Myelodysplastic Syndromes (MDS) |
|
HDAC4 inhibition disrupts TET2 function in high-risk MDS and AML |
Jul 2020 |
Aging |
Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS) |
|
Prognostic significance of serial molecular annotation in myelodysplastic syndromes (MDS) and secondary acute myeloid leukemia (sAML) |
Jul 2020 |
Leukemia |
Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS) |
|
Chronic fatigue in myelodysplastic syndromes: Looking beyond anemia |
Jul 2020 |
Critical reviews in hematology/oncology |
Myelodysplastic Syndromes (MDS) |
|
Eat and be healthy: nutritional status in myelodysplastic syndromes |
Jul 2020 |
Leukemia & Lymphoma |
Myelodysplastic Syndromes (MDS) |
|
Patient and physician perceptions about blood transfusions in the myelodysplastic syndromes |
Jul 2020 |
Leukemia Research |
Myelodysplastic Syndromes (MDS) |
|
Consensus minimum hemoglobin level above which patients with myelodysplastic syndromes can safely forgo transfusions |
Jul 2020 |
Leukemia & Lymphoma |
Myelodysplastic Syndromes (MDS) |
|
Glasdegib as maintenance therapy for patients with AML and MDS patients at high risk for postallogeneic stem cell transplant relapse |
Jul 2020 |
Blood Advances |
Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS) |
